Drug Shortage Report for TEVA-COTRIDIN EXPECTORANT
Report ID | 129053 |
Drug Identification Number | 02053403 |
Brand name | TEVA-COTRIDIN EXPECTORANT |
Common or Proper name | COTRIDIN EXPECTORANT SYRUP |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | TRIPROLIDINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE GUAIFENESIN CODEINE PHOSPHATE |
Strength(s) | 2MG 30MG 100MG 10MG |
Dosage form(s) | SYRUP |
Route of administration | ORAL ORAL |
Packaging size | 500ml |
ATC code | R05FA |
ATC description | COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-11-25 |
Estimated end date | |
Actual end date | 2021-03-17 |
Shortage status | Resolved |
Updated date | 2021-03-18 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-11-27 | English | Compare |
v2 | 2020-11-27 | French | Compare |
v3 | 2021-03-18 | English | Compare |
v4 | 2021-03-18 | French | Compare |
Showing 1 to 4 of 4